Pages that link to "Q27659493"
Jump to navigation
Jump to search
The following pages link to RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth (Q27659493):
Displaying 50 items.
- Raf-1 proto-oncogene, serine/threonine kinase (Q410434) (← links)
- Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions (Q21004109) (← links)
- A-Raf proto-oncogene, serine/threonine kinase (Q21109211) (← links)
- B-Raf proto-oncogene, serine/threonine kinase (Q21109218) (← links)
- NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo (Q21132689) (← links)
- p21-Activated kinase 1 (Pak1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112 (Q21134956) (← links)
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner (Q21629049) (← links)
- RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation (Q24292999) (← links)
- Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia (Q24299821) (← links)
- Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling (Q24302450) (← links)
- Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas (Q24303940) (← links)
- Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling (Q24314807) (← links)
- Raf family kinases: old dogs have learned new tricks (Q24316181) (← links)
- A secretory kinase complex regulates extracellular protein phosphorylation (Q24323147) (← links)
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib (Q24594790) (← links)
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (Q24597152) (← links)
- Analysis of the genome to personalize therapy for melanoma (Q24601008) (← links)
- Complexity in KSR function revealed by Raf inhibitor and KSR structure studies (Q24603489) (← links)
- PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells (Q24606438) (← links)
- Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF (Q24615826) (← links)
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation (Q24629474) (← links)
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation (Q24631953) (← links)
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations (Q24632064) (← links)
- The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer (Q26747247) (← links)
- KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment (Q26751520) (← links)
- Phytochemicals for the Management of Melanoma (Q26766708) (← links)
- Somatic DNA mutation analysis in targeted therapy of solid tumours (Q26770324) (← links)
- MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy (Q26771192) (← links)
- Melanoma: oncogenic drivers and the immune system (Q26775598) (← links)
- Tailoring the Treatment of Melanoma: Implications for Personalized Medicine (Q26775806) (← links)
- Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma (Q26795510) (← links)
- Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance (Q26795609) (← links)
- Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets (Q26795735) (← links)
- Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet (Q26799864) (← links)
- Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges (Q26823978) (← links)
- Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma (Q26824310) (← links)
- Ten things you should know about protein kinases: IUPHAR Review 14 (Q26849417) (← links)
- The dynamic nature of the kinome (Q26852588) (← links)
- PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms (Q26862544) (← links)
- Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? (Q27001584) (← links)
- Multiscale models of cell signaling (Q27010700) (← links)
- Targeted therapies in development for non-small cell lung cancer (Q27022852) (← links)
- Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options (Q27023596) (← links)
- Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond (Q27026323) (← links)
- Photoactivated localization microscopy with bimolecular fluorescence complementation (BiFC-PALM) for nanoscale imaging of protein-protein interactions in cells (Q27322523) (← links)
- Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors (Q27333987) (← links)
- Cofactor-mediated conformational control in the bifunctional kinase/RNase Ire1 (Q27670678) (← links)
- Chemical genetic strategy for targeting protein kinases based on covalent complementarity (Q27671824) (← links)
- Active site profiling reveals coupling between domains in SRC-family kinases (Q27675080) (← links)
- Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization (Q27678182) (← links)